bioAffinity Technologies, Inc. (BIAF)
9.70
-0.80
(-7.62%)
USD |
NASDAQ |
Sep 10, 14:41
bioAffinity Technologies Enterprise Value : 3.753M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 3.753M |
| September 08, 2026 | 3.043M |
| September 04, 2026 | 5.910M |
| September 03, 2026 | 4.784M |
| September 02, 2026 | 3.414M |
| September 01, 2026 | 1.985M |
| August 31, 2026 | 1.067M |
| August 28, 2026 | 1.208M |
| August 27, 2026 | 1.293M |
| August 26, 2026 | 1.307M |
| August 25, 2026 | 1.352M |
| August 24, 2026 | 1.637M |
| August 21, 2026 | 1.718M |
| August 20, 2026 | 1.719M |
| August 19, 2026 | 1.780M |
| August 18, 2026 | 2.216M |
| August 17, 2026 | 1.664M |
| August 14, 2026 | 1.733M |
| August 13, 2026 | 1.603M |
| August 12, 2026 | 2.212M |
| August 11, 2026 | 2.302M |
| August 10, 2026 | 2.329M |
| August 07, 2026 | 2.465M |
| August 06, 2026 | 2.598M |
| August 05, 2026 | 2.599M |
| Date | Value |
|---|---|
| August 04, 2026 | 2.739M |
| August 03, 2026 | 3.057M |
| July 31, 2026 | 3.261M |
| July 30, 2026 | 3.376M |
| July 29, 2026 | 2.973M |
| July 28, 2026 | 3.268M |
| July 27, 2026 | 3.629M |
| July 24, 2026 | 3.481M |
| July 23, 2026 | 3.535M |
| July 22, 2026 | 3.807M |
| July 21, 2026 | 3.788M |
| July 20, 2026 | 3.746M |
| July 17, 2026 | 3.778M |
| July 16, 2026 | 3.833M |
| July 15, 2026 | 3.905M |
| July 14, 2026 | 3.817M |
| July 13, 2026 | 3.753M |
| July 10, 2026 | 4.205M |
| July 09, 2026 | 4.284M |
| July 08, 2026 | 4.357M |
| July 07, 2026 | 4.635M |
| July 06, 2026 | 4.487M |
| July 02, 2026 | 4.635M |
| July 01, 2026 | 4.727M |
| June 30, 2026 | 4.513M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 266.28M |
| Perspective Therapeutics, Inc. | 108.20M |
| MiMedx Group, Inc. | 563.36M |
| Veracyte, Inc. | 3.080B |
| ABVC BioPharma, Inc. | 29.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.366M |
| Revenue (Quarterly) | 1.511M |
| Total Expenses (Quarterly) | 4.877M |
| EPS Diluted (Quarterly) | -9.660 |
| Gross Profit Margin (Quarterly) | 23.91% |
| Profit Margin (Quarterly) | -222.8% |
| Earnings Yield | -1.06K% |
| Normalized Earnings Yield | -785.94 |